Digital From engagement metrics to meaningful experience: Why pharma... Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs
Digital How GenAI is cracking the toughest targets in drug discovery Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).
Digital Pharma's quantum leap: How AI is redefining media measuremen... Welcome to the era where the convergence of quantum computing and artificial intelligence isn't just an advantage, it's the imperative.
Digital AI's promise, biotech's peril: How unequal access to computi... Many biotechs remain locked out of the AI revolution by a combination of cost, complexity, and lack of access to state-of-the-art infrastructure.
Digital JPM2026: Broadening AI drug discovery to include the lab, wi... Yann Gaston-Mathe, founder and CEO of Iktos, discusses AI drug discovery's shift to real-world operations that are able to incorporate wet lab data.
Digital Is DTx finally reaching drug-like efficacy? A Q&A with David... Click Therapeutics CEO David Benshoof Klein shares thoughts on what's been holding DTx back and why this could be the moment for a breakout.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.